Hinge Health’s (HNGE) Market Outperform Rating Reaffirmed at Citizens Jmp

Citizens Jmp restated their market outperform rating on shares of Hinge Health (NYSE:HNGE) in a research report report published on Wednesday morning,Benzinga reports. They currently have a $65.00 price target on the stock.

HNGE has been the topic of a number of other research reports. Wells Fargo & Company began coverage on shares of Hinge Health in a report on Thursday, January 8th. They issued an “overweight” rating and a $68.00 price target on the stock. KeyCorp decreased their target price on Hinge Health from $72.00 to $70.00 and set an “overweight” rating for the company in a research report on Thursday, January 8th. Barclays dropped their price target on Hinge Health from $60.00 to $52.00 and set an “overweight” rating on the stock in a research report on Wednesday. Stifel Nicolaus set a $59.00 price target on Hinge Health in a research note on Thursday, February 5th. Finally, Freedom Capital upgraded Hinge Health to a “strong-buy” rating in a research note on Thursday, January 22nd. One investment analyst has rated the stock with a Strong Buy rating, eighteen have issued a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $57.71.

Hinge Health Stock Performance

NYSE HNGE opened at $38.60 on Wednesday. The company has a market capitalization of $3.04 billion and a PE ratio of -2.94. Hinge Health has a 52-week low of $30.08 and a 52-week high of $62.18. The company has a 50-day simple moving average of $43.96 and a 200 day simple moving average of $48.86.

Hinge Health declared that its Board of Directors has authorized a stock buyback plan on Wednesday, November 12th that authorizes the company to repurchase $250.00 million in shares. This repurchase authorization authorizes the company to repurchase up to 7.2% of its stock through open market purchases. Stock repurchase plans are typically an indication that the company’s board believes its shares are undervalued.

Insider Buying and Selling at Hinge Health

In other Hinge Health news, President James Pursley sold 15,000 shares of the firm’s stock in a transaction dated Monday, December 22nd. The stock was sold at an average price of $48.40, for a total value of $726,000.00. Following the completion of the transaction, the president owned 769,778 shares in the company, valued at $37,257,255.20. This trade represents a 1.91% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Kristina M. Leslie sold 1,250 shares of Hinge Health stock in a transaction dated Friday, November 21st. The shares were sold at an average price of $45.68, for a total value of $57,100.00. Following the transaction, the director directly owned 27,750 shares of the company’s stock, valued at $1,267,620. The trade was a 4.31% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 2,805,105 shares of company stock worth $128,216,614 in the last three months.

Institutional Trading of Hinge Health

Several institutional investors and hedge funds have recently bought and sold shares of the company. Mirae Asset Global Investments Co. Ltd. bought a new position in Hinge Health in the 3rd quarter valued at $37,000. First Horizon Corp raised its position in shares of Hinge Health by 163.9% in the fourth quarter. First Horizon Corp now owns 855 shares of the company’s stock worth $40,000 after buying an additional 531 shares in the last quarter. Montag A & Associates Inc. bought a new stake in Hinge Health during the second quarter valued at $41,000. High Point Wealth Management LLC purchased a new position in Hinge Health during the fourth quarter worth about $46,000. Finally, SBI Securities Co. Ltd. bought a new position in Hinge Health in the 2nd quarter worth about $48,000.

Key Hinge Health News

Here are the key news stories impacting Hinge Health this week:

• Positive Sentiment: Q4 results beat across the board — EPS and revenue topped expectations and revenue grew ~45.5% year‑over‑year, driving the rally. Earnings Report
• Positive Sentiment: Hinge raised FY2026 revenue guidance to roughly $732M–$742M (above consensus) and issued Q1 revenue guidance above estimates — a clear reason for investor optimism. Press Release
• Positive Sentiment: Company outlined a ~25% revenue growth target for 2026 and said AI-driven care investments will help scale offerings — supports the medium‑term growth story. AI & Guidance Coverage
• Positive Sentiment: Analysts remain largely constructive: Needham reaffirmed a Buy ($59 PT) and Citizens/JMP kept an Outperform with a $65 target — these notes support further upside from current levels. Analyst Notes Tickerreport
• Neutral Sentiment: Barclays trimmed its price target from $60 to $52 but kept an Overweight rating — mixed signal: still positive stance but a more conservative valuation. Barclays Note
• Neutral Sentiment: Full earnings call transcript is available for detail on margins, win rates, and cash generation — useful for confirming sustainability of trends. Earnings Transcript
• Negative Sentiment: Despite strong results, the stock trades below its 50‑ and 200‑day moving averages and carries a negative trailing P/E; if growth slows or margins disappoint, multiple compression risks exist.

Hinge Health Company Profile

Hinge Health (NYSE: HNGE) is a digital musculoskeletal (MSK) clinic that provides end-to-end solutions for the prevention and management of musculoskeletal conditions. The company’s platform combines wearable motion sensors, personalized exercise therapy guided by licensed physical therapists, and behavioral health coaching to deliver tailored treatment plans. By integrating technology with evidence-based clinical protocols, Hinge Health aims to reduce pain, improve mobility and decrease reliance on more invasive interventions such as surgery or opioid prescriptions.

Founded in 2015 and headquartered in San Francisco, Hinge Health partners with employers, health plans and other payers to offer its self-directed, app-based programs.